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Abstract
Objective: α-Synuclein has been studied as a potential biomarker for Parkinson’s disease (PD) with no concluding
results. Accordingly, there is an urgent need to find out reliable specific biomarkers for PD. GPR37 is an orphan G
protein-coupled receptor that toxically accumulates in autosomal recessive juvenile parkinsonism. Here, we
investigated whether GPR37 is upregulated in sporadic PD, and thus a suitable potential biomarker for PD.
Methods: GPR37 protein density and mRNA expression in postmortem substantia nigra (SN) from PD patients were
analysed by immunoblot and RT-qPCR, respectively. The presence of peptides from the N-terminus-cleaved domain
of GPR37 (i.e. ecto-GPR37) in human cerebrospinal fluid (CSF) was determined by liquid chromatography-mass
spectrometric analysis. An engineered in-house nanoluciferase-based immunoassay was used to quantify ecto-
GPR37 in CSF samples from neurological control (NC) subjects, PD patients and Alzheimer’s disease (AD) patients.
Results: GPR37 protein density and mRNA expression were significantly augmented in sporadic PD. Increased
amounts of ecto-GPR37 peptides in the CSF samples from PD patients were identified by mass spectrometry and
quantified by the in-house ELISA method. However, the CSF total α-synuclein level in PD patients did not differ
from that in NC subjects. Similarly, the cortical GPR37 mRNA expression and CSF ecto-GPR37 levels in AD patients
were also unaltered.
Conclusion: GPR37 expression is increased in SN of sporadic PD patients. The ecto-GPR37 peptides are significantly
increased in the CSF of PD patients, but not in AD patients. These results open perspectives and encourage further
clinical studies to confirm the validity and utility of ecto-GPR37 as a potential PD biomarker.
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Background
Parkinson’s disease (PD) is the second most common
type of neurodegenerative disorder [1], with hallmarks of
Lewy body (LB) formation and neuronal death and syn-
aptic loss in the substantia nigra (SN) [2]. Cerebrospinal
fluid (CSF) is an accessible source of brain-derived pro-
teins and metabolites, which mirrors molecular changes
that occur in the central nervous system. The decreased
CSF levels of amyloid-β 42 (Aβ42) and altered content
of tau protein species are used in clinical practice to aid
diagnosis of Alzheimer’s disease (AD) [3]. In contrast, al-
though potential diagnostic/prognostic CSF biomarkers
of PD (i.e. α-synuclein species, lysosomal enzymes,
markers of Aβ and tau pathology, and neurofilament
light chain) have been largely assessed, no conclusive
data have been obtained. However, the combined assess-
ment of some of these biomarkers in PD patients can
provide more accurate diagnostic and prognostic results,
which necessitate systematic studies confirming the val-
idity and utility of combinations of certain CSF (and
blood) PD/AD biomarkers for clinical practice [4, 5].
GPR37 is an orphan G protein-coupled receptor
(GPCR) expressed in brain regions such as cerebellum,
corpus callosum, caudate nucleus, putamen, hippocam-
pus and SN [6, 7]. The physiological function of this re-
ceptor has yet to be elucidated. A recent study has
shown that GPR37 mediates the control of oligodendro-
cyte differentiation [8], but there is little information on
the role of GPR37 in other glial cells and neurons.
GPR37 is also known as a parkin-associated endothelin-
receptor-like receptor (Pael receptor) [9] as it was ori-
ginally identified as a substrate of parkin, an E3 ubiquitin
ligase encoded by the PARK2 gene involved in ubiquiti-
nation and proteasome-mediated degradation/clearance
of misfolded proteins [9–11]. Mutations in the PARK2
gene that lead to the loss of the ubiquitin ligase activity
of parkin are the most common cause of autosomal re-
cessive juvenile parkinsonism [10]. Consistently, an in-
soluble form of GPR37 has been reported to accumulate
in the brains of AR-JP patients [9], suggesting a neuro-
pathological role of this receptor in PD. In line with this,
mice lacking GPR37 are partially protected against dopa-
minergic cell death caused by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine [12]. Nevertheless, in heterologous
expression systems, GPR37 matures and is exported
from the endoplasmic reticulum to the cell surface,
where its long extracellular N-terminus is rapidly and
constitutively cleaved by metalloproteinases (MPs) [13].
Thus, the GPR37 ectodomain (i.e. ecto-GPR37) is re-
leased from cells by shedding, a phenomenon rarely de-
scribed for GPCRs. Importantly, MPs have received
much attention since they can cleave a large number of
protein substrates (i.e. α-synuclein, amyloid precursor
protein, and Apolipoprotein E receptor), thus playing a
potential role in neurodegenerative diseases. Indeed, al-
tered levels of MPs have been described in post-mortem
brain samples from PD [14] and AD [15, 16] subjects.
Here, we set out to assess the expression of GPR37 in
sporadic PD and the presence of ecto-GPR37 peptides in
CSF of PD patients. We engineered an in-house im-
munoassay to assess ecto-GPR37 levels in CSF samples
from two different cohorts of PD patients along with
age- and gender-matched neurological control (NC) sub-




The following antibodies were used: rabbit anti-human-
GPR37-N polyclonal antibody [17], rabbit anti-mouse-
GPR37-N polyclonal antibody [7, 18], rabbit anti-pan-
GPR37-C polyclonal antibody [18], mouse anti-β-actin
monoclonal antibody (A5316; Sigma-Aldrich, St. Louis,
MO) and rabbit anti-α-actinin polyclonal antibody
(Santa Cruz Biotechnology Inc., Dallas, TX).
Human post-mortem brain samples
Human post-mortem brain tissues and CSF samples
were obtained from the Institute of Neuropathology
HUB-ICO-IDIBELL Biobank and the Hospital Clinic-
IDIBAPS Biobank following the guidelines of Spanish le-
gislation on this matter (Real Decreto de Biobancos
1716/2011) [19, 20] and upon approval of the local eth-
ics committees. The pathological cases were categorized
as PD (LB disease pathology) or AD (neurofibrillary tan-
gle [NFT] pathology) at stages 1–6 according to the no-
menclature of Braak et al. [21, 22]. The post-mortem
delay (PMD) between death and tissue processing was
between 2.5 h and 20.35 h. One hemisphere was immedi-
ately cut into 1-cm-thick coronal sections, and selected
areas of the encephalon were rapidly dissected, frozen
on metal plates over dry ice, placed in individual air-
tight plastic bags and stored at − 80 °C until use for bio-
chemical studies. The other hemisphere was fixed by
immersion in 4% buffered formalin for 3 weeks for mor-
phological studies. The neuropathological diagnosis of
all cases was made based on the evaluation of 20 se-
lected de-waxed paraffin sections containing regions of
the cerebral cortex, diencephalon, thalamus, brain stem
and cerebellum, which were stained with haematoxylin,
eosin and Klüver-Barrera. Only cases categorized as
stages 3, 4, 5 and 6 (i.e. PD or AD stage 3–6) were con-
sidered. Cases with concomitant tauopathies with NFT
and A-B stages of Aβ plaque [22] were excluded from
the present study. The middle-aged control cases had
not suffered from neurologic, psychiatric, or metabolic
diseases (including metabolic syndrome), and did not
have abnormalities in the neuropathological examination
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excepting stages 1–2 of NFT pathology and phases A-B
of Aβ plaques. Cases with associated pathologies such as
vascular disease (except mild atherosclerosis and arterio-
losclerosis), TDP-43 proteinopathy, infections of the ner-
vous system, brain neoplasm, systemic and central
immune diseases, metabolic syndrome and hypoxia were
excluded from the present study. The selected brain
areas were SN, frontal cortex (FC) and entorhinal cortex
(EC), and different series of samples (i.e. NCs, Braak PD/
AD stage 3, Braak PD/AD 4, Braak PD/AD 5 and Braak
PD/AD 6) were prepared according to their experimen-
tal use: (i) PD SN immunoblotting: 5 NCs (3 males and
2 females; mean age: 84.2 ± 7 years; PMD: 10.7 ± 7.7 h),
5 Braak PD stage 4 (3 males and 2 females; mean age:
77.6 ± 7.6 years; PMD: 10.1 ± 8.2 h), 5 Braak PD stage 5
(3 males and 2 females; mean age: 80.6 ± 6.4 years; PMD:
10.8 ± 5.2 h) and 5 Braak PD stage 6 (3 males and 2 fe-
males; mean age: 76.2 ± 7.25 years; PMD: 9.8 ± 5.5 h)
cases; (ii) PD SN RT-qPCR: 10 NCs (8 males and 2 fe-
males; mean age: 61.4 ± 12.8 years; PMD: 5.7 ± 3.5 h;
RNA integrity number [RIN]: 6.6 ± 0.4), 7 Braak PD
stage 3/4 (3 males and 4 females; mean age: 78 ± 5.9
years; PMD: 5.5 ± 1.2 h; RIN: 7.2 ± 0.5) and 17 Braak PD
stage 5/6 (12 males and 5 females; mean age: 79.8 ± 4.9
years; PMD: 8.6 ± 3.4 h; RIN: 7.1 ± 0.6) cases; (iii) AD FC
RT-qPCR: 17 NCs (10 males and 7 females; mean age:
61.5 ± 14.4 years; PMD: 5.1 ± 1.9 h; RIN: 7.5 ± 0.6), 9
Braak AD stage 3/4 (4 males and 5 females; mean age:
78.6 ± 8.1 years; PMD: 6.7 ± 3.5 h; RIN: 7.7 ± 1) and 20
Braak AD stage 5/6 (9 males and 11 females; mean age:
80.5 ± 6.9 years; PMD: 9.3 ± 5.8 h; RIN: 7.5 ± 0.8); and
(iv) AD EC RT-qPCR: 5 NCs (4 males and 1 female;
mean age: 41.7 ± 9.7 years; PMD: 5.5 ± 0.8 h; RIN: 6.3 ±
0.9), 4 Braak AD stage 3/4 (3 males and 1 female; mean
age: 80.5 ± 1 years; PMD: 6.6 ± 4.2 h; RIN: 6.2 ± 0.7) and
5 Braak AD stage 5/6 (3 males and 2 females; mean age:
79.2 ± 5.1 years; PMD: 7.9 ± 4 h; RIN: 6.2 ± 0.8).
Participants
PD patients were recruited at the movement disorders
clinic at Karolinska University Clinic, Huddinge, Sweden.
Patients underwent a clinical examination (including rat-
ings of motor, cognitive and psychiatric symptoms) by
an experienced neurologist (PS) (Table 1). All the in-
cluded patients were followed longitudinally and PD
diagnosis, including subsequent responsiveness to dopa-
minergic therapy, was confirmed before they were in-
cluded in the CSF analysis. Hence, the PD patients
satisfied the clinical diagnosis of PD according to the
U.K. Parkinson Disease Society Brain Bank diagnostic
criteria. Motor symptoms were evaluated with the Uni-
fied Parkinson’s Disease Scale (UPDRS) part 3 in the ON
state of medication cycle. Non-motor and motor symp-
toms in daily activities were evaluated with UPDRS part
1 and part 2, respectively. UPDRS part 4 was used to
measure motor complications [23]. Almost all patients
had available scores for Hoehn & Yahr scale (n = 40)
assessing motor impairment [24], and 66% of the patients
had available Montreal Cognitive Assessment scores
(MoCA, n = 28) evaluating the cognitive impairment
[25]. In addition, within the routine visit self-evaluation
questionnaires were implemented, including Non-Motor
Symptoms Questionnaire (n = 26) [26], and Hospital
Anxiety and Depression scale (n = 26) [27]. Finally, med-
ications were presented as L-dopa equivalent doses [28].
Thirteen patients were drug-naïve, de novo, patients at
the time of lumbar puncture. Age- and gender-matched
control subjects were recruited from routine neurology
examinations. Control patients were also recruited at
Karolinska University Clinic, Huddinge, Sweden and
were diagnosed with benign neurological diagnoses, such
as tension headache with no evidence of dementia, no
cognitive complaints, no PD or other brain disease, and
thus were defined as NCs.
CSF samples
For preliminary assessment of ecto-GPR37 in humans,
we used post-mortem CSF samples from eight PD
pathological cases (six males and two females, mean age:
71.4 ± 9.9 years; post-mortem interval: 6.6 ± 3.7 h)
(neuropathology confirmed from Bellvitge Hospital
Neuropathology Service, see above) and eight age-
matched control cases (all male; mean age: 66.8 ± 5.2
years; post-mortem interval: 6.4 ± 2.3 h). Subsequently,
CSF samples were obtained by lumbar puncture from
participants from Karolinska University Clinic, collected
into polypropylene-tubes and immediately centrifuged at
1800 × g at 4 °C for 10 min before being stored in
Table 1 Demographic and clinical characteristics of the study
participants. Participants were recruited at the movement
disorders clinic at Karolinska University Clinic, Huddinge,
Sweden. Patients underwent a clinical examination as described
in the Methods section
NC PD
Age (years) 64 ± 12 64 ± 11
Sex (M/F) 27/18 23/18
Disease duration (years) — 5.8 ± 5.5
UPDRS Total (n = 26) — 42 ± 18
UPDRS III (n = 26) — 26 ± 14
H&Y score (n = 40) — II
MoCA (n = 28) — 23 ± 5
HADS (n = 26) — 14 ± 8
LED (n = 28) — 709 ± 512
Data are expressed as mean ± SD except the Hoehn and Yahr (H&Y) score as
median. UPDRS Unified Parkinson’s Disease Scale; MoCA Montreal Cognitive
Assessment scores; HADS Hospital Anxiety and Depression scale; LED L-dopa
equivalent dose
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aliquots of 100 μl at − 80 °C as previously described [29].
Thus, CSF samples from a total of 86 participants (45
NCs and 41 PD patients out of whom 12 were drug-
naïve) were used in the study.
For the analysis of CSF ecto-GPR37 in AD, NC (9
males and 13 females; mean age: 65.7 ± 6.7 years) and
AD (10 males and 13 females; mean age: 67.6 ± 7.9 years)
participants were enrolled at the Department of Neur-
ology, Clinical Dementia Center of Göttingen
(Germany). The NC participants were those diagnosed
with non-primarily neurodegenerative neurological and
psychiatric diseases. AD was diagnosed according to the
guideline of the National Institute on Aging–Alzheimer’s
Association workgroups [30]. All the participants had
given consent for the use of their clinical data and CSF
for research purposes, and the study was approved by
the regional ethics committee for medical research in
Stockholm (2011/500–31/1 and 2012/2224–32/4). All
procedures followed were in accordance with the ethical
standards indicated by the Declaration of Helsinki of
1975, as revised in 2000.
Animals
C57BL/6 J wild-type (GPR37+/+) and GPR37-KO
(GPR37−/−) male mice (Strain Name: B6.129P2-
GPR37tm1Dgen/J; The Jackson Laboratory, Bar Harbor,
ME) at 8 weeks of age were used [7]. Animal protocols
were approved by the University of Barcelona Commit-
tee on Animal Use and Care. Animals were housed and
tested in compliance with the guidelines described in the
Guide for the Care and Use of Laboratory Animals [31]
and following the European Union directives (2010/63/
EU), Federation for Laboratory Animal Science Associa-
tions, and Animal Research: Reporting In Vivo Experi-
ments guidelines. All efforts were made to minimize
animal suffering and the number of animals used. All
animals were housed in groups of five in standard cages
with ad-libitum access to food and water under a 12-h
dark/light cycle (starting at 7:30 AM) at 22 °C with 66%
humidity (standard conditions).
Mouse CSF samples
Mice were anesthetized by intraperitoneal administra-
tion of a mixture of ketamine (100 mg/kg, Merial,
Spain)/xylazine (10 mg/kg, Calier, Spain). The animal
was stereotaxically immobilized to facilitate the access
to the cisterna magna through a sagittal incision just
behind the occiput. CSF (~ 10 μl) was collected by
puncturing the cisterna magna with a micro-fine
(30G) 3-mL syringe-needle. The CSF samples were
frozen immediately on dry ice and kept at − 80 °C
until use.
Human brain extract preparation
The post-mortem human SN tissue (0.1 g of fresh tissue)
was homogenized in ice-cold lysis buffer containing 10
mM Tris HCl, 1 mM EDTA, 300mM KCl (pH 7.4) and a
protease inhibitor cocktail (Roche Molecular Systems,
Pleasanton, CA) using a Polytron for 3 × 10 s on ice. The
homogenate was centrifuged at 1000 × g for 10 min at
4 °C. The resulting supernatant was centrifuged at 12,
000 × g for 30 min at 4 °C. The resulting pellet was dis-
persed in 50mM Tris HCl (pH 7.4) and 10mM MgCl2,
washed, and resuspended in the same medium. Protein
concentration was determined using the bicinchoninic
acid (BCA) protein assay kit (ThermoFisher Scientific)
and 50–80 μg of protein was used for immunoblotting.
Gel electrophoresis and immunoblotting
Brain proteins were separated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
then transferred to polyvinylidene difluoride membranes
using the Trans-Blot®Turbo™ transfer system (Bio-Rad)
at 25 mV for 30min. Non-specific binding was blocked
by incubation with 5% milk in PBS containing 0.05%
Tween for 1 h at room temperature. After washing, the
membranes were incubated at 4 °C overnight with the
indicated primary antibody in PBS containing 5% milk
and 0.05% Tween. Then the membranes were incubated
for 1 h with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody and the immune-
complexes were revealed with a chemiluminescence re-
agent (ECL, Amersham, GE Healthcare, Buckingham-
shire, UK) using an Amersham Imager 600 (GE
Healthcare Europe GmbH, Barcelona, Spain). The gel
protein loading was assessed by using the rabbit anti-α-
actinin polyclonal antibody (1 μg/ml). Protein bands
were quantified by densitometric scanning and analysed
with the Image J program (National Institutes of Health,
Bethesda, MA).
RNA purification and reverse transcription
RNA was extracted from human post-mortem SN, FC
or EC tissues using the RNeasy Lipid Tissue Mini Kit
(Qiagen, Hilden, Germany) following the manufacturer’s
protocol, in combination with DNase digestion to avoid
extraction and later amplification of genomic DNA. The
concentration of each sample was determined by absorb-
ance at 260 nm using a NanoDrop 2000 spectrophotom-
eter (ThermoFisher Scientific). RNA integrity was
determined using the Agilent 2100 BioAnalyzer (Agilent,
Santa Clara, CA). Special care was taken to assess pre-
mortem and post-mortem factors, which may interfere
with RNA processing [32]. Bivariate analyses were car-
ried out to detect the association of our variables with
potential confounding factors (age, PMD and RIN) using
Spearman or Pearson correlations for quantitative
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variables. PMD had no effect on RIN values in the
present post-mortem samples used (data not shown).
Reverse transcription of the RNA samples was carried
out with the High-Capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA) and the Gene Amp® 9700
PCR System thermocycler (Applied Biosystems). A par-
allel reaction for an RNA sample was processed in the
absence of reverse transcriptase to rule out DNA
contamination.
qPCR
Real-time quantitative PCR (RT-qPCR) assays were con-
ducted in duplicate on 1000 ng of cDNA samples ob-
tained from the reverse-transcription reaction, diluted at
1:20 in 384-well optical plates (Kisker Biotech, Steinfurt,
GE), using the ABI Prism 7900 HT Sequence Detection
System (Applied Biosystems). Parallel amplification reac-
tions were carried out using 20× TaqMan Gene Expres-
sion Assays and 2× TaqMan Universal PCR Master Mix
(Applied Biosystems). β-Glucuronidase (GUS-β; Ref:
Hs00939627_m1), X-prolyl aminopeptidase (aminopepti-
dase P) 1 (XPNPEP1, Ref: Hs00958026_m1), alanyl-
transfer RNA synthase (AARS, Ref: Hs00609836_m1)
and hypoxanthine-guanine phosphoribosyltransferase
(HPRT, ref: Hs02800695_m1) were used as housekeeping
genes for normalization of GPR37 (Ref: Hs00173744_
m1) expression. The selection of these housekeeping
genes was based on previous data showing low vulner-
ability in the brains of several human neurodegenerative
diseases [32, 33]. The RT-qPCR reactions were per-
formed at 50 °C for 2 min, 95 °C for 10 min, and 40 cy-
cles of 95 °C for 15 s and 60 °C for 1 min. TaqMan PCR
data were captured using the Sequence Detection Soft-
ware (SDS version 2.2, Applied Biosystems). Subse-
quently, the threshold cycle (CT) data for each sample
were analyzed with the ΔΔCT method. First, ΔCT values
were calculated as the normalized CT values for each
target gene in relation to the mean values of GUS-β,
XPNPEP1, AARS and HPRT. Second, the ΔΔCT values
were obtained by the ΔCT of each sample minus the
mean ΔCT of the population of control samples (calibra-
tor samples). The fold-change was determined using the
eq. 2-ΔΔCT.
Generation of the ecto-GPR37 constructs
The human and mouse GPR37 were tagged at its N-
terminal tail with either NanoLuc (NL) luciferase or the
O6-alkylguanine-DNA alkyltransferase (AGT) to allow
further luminescence or AGT substrate (i.e. SNAP tag)
detection, respectively. In addition, an haemagglutinin
(HA) epitope was also inserted to allow HA-based purifi-
cation from cells expressing the corresponding con-
structs. First, the HA-epitope cDNA sequence was
inserted into the pNFL1-secN plasmid (Promega,
Madison, WI) using the QuikChange II Site-Directed
Mutagenesis Kit (Stratagene, San Diego, CA) and the fol-
lowing primer pairs: FNLHA: (5′-GCCGGATTAT
GCGGCGATCGCTTCCGAATTCAGAGCTCAAC-3′)
and RNLHA (5′-ACATCATACGGATAGCCGCT
CGAGCCCGCCAG-3′). Subsequently, the cDNA en-




The amplified mouse GPR37 insert was then cloned into
the XbaI/NotI sites of pNFL1-secN-HA plasmid, thus
providing the pNFL-HA-mGPR37NL construct. Similarly,
the human GPR37 was amplified using the primers
FNLXbaIhGPR37 (5′-AAACATCTAGAGCCCTCGG
GGTCGCCCCT-3′) and RNLNotIhGPR37 (5′-
CGAGCGGCCGCTCAGCAATGAGTTCCGACAG-3′)
and the amplified human GPR37 insert was cloned into
the EcoRV/NotI sites of pNFL1-secN-HA plasmid to
provide the pNFL-HA-hGPR37NL construct. Finally, the
pRK5-HA-mGPR37SNAP and pRK5-HA-hGPR37SNAP
constructs were obtained by amplifying mouse GPR37
with primers FpRK5EcoRVmGPR37 (5′-AAACAGATA
TCGCTGCCCTGAGCTTTGTCCCT-3′) and RNo-
tINLmGPR37 (5′-AAGCGGCCGCTCAGCAATGA
GTCCCCAC-3′), and human GPR37 with primers
FpRK5XhoImGPR37 (5′-AAACACTCGAGGCCCTCGG
GGTCGCCCCT-3′) and RNLNotImGPR37 (5′-
CGAGCGGCCGCTCAGCAATGAGTTCCGACAG-3′).
The amplified mouse or human GPR37 insert was then
cloned into the EcoRV/NotI and XhoI/NotI sites of
pRK5-HA plasmid, thus providing the pRK5-HA-
mGPR37SNAP and the pRK5-HA-hGPR37SNAP con-
structs, respectively. All the constructs were verified by
DNA sequencing.
Cell culture and ecto-GPR37 recombinant protein
production
Human embryonic kidney (HEK)-293 T cells (American
Type Tissue Culture, Manassas, VA) were grown in Dul-
becco’s modified Eagle’s medium (DMEM) (Sigma-Al-
drich) supplemented with 1 mM sodium pyruvate, 2
mM L-glutamine, 100 U/ml streptomycin, 100 mg/ml
penicillin and 5% (v/v) fetal bovine serum at 37 °C in an
atmosphere of 5% CO2. Cells were passaged at 80–90%
confluency.
HEK-293 T cells grown on 10-cm culture dishes were
transiently transfected with the pNFL-HA-mGPR37NL,
pNFL-HA-hGPR37NL, pRK5-HA-mGPR37SNAP or
pRK5-HA-hGPR37SNAP construct using the polyethyle-
nimine method [34]. After 24 h, the culture medium was
replaced with DMEM and the supernatant was collected
48 h and 72 h after transfection. For purification of the
expressed recombinant proteins, the supernatant was
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first centrifuged at 1000×g for 5 min to remove cell deb-
ris, and then concentrated and dialysed in Tris-buffered
saline (TBS, 50 mM Tris-Cl, 150 mM NaCl, pH 7.5)
using an Amicon-Ultra-15 10 K falcon tube (Merck,
Darmstadt, Germany) upon continuous centrifugation at
3000×g at 4 °C until red phenol was not observed. Sub-
sequently, the supernatant was incubated with Pierce™
anti-HA agarose (1 ml, ThermoFisher Scientific, Inc.,
Rockford, IL) in an end-over-end rotator overnight at
4 °C. After packing and washing the resin with TBS, the
recombinant proteins were eluted with glycine-HCl pH
2.5, collected in 1 ml fractions and rapidly neutralized
with Tris-base (pH 8.8). Fractions containing the purified
recombinant proteins (i.e. mGPR37NL, hGPR37NL,
mGPR37SNAP or hGPR37SNAP) were analysed by immu-
noblot and the luminescence of NL-containing con-
structs was determined. Finally, the purified proteins
were concentrated 40-fold using an Amicon-Ultra-4 3 K
falcon tube (Merck) upon continuous centrifugation at
4000×g at 15 °C, and then diluted (1:100) in a buffer
containing 10 mM Tris-HCl and 150 mM NaCl, pH 7.4
in a total volume of 400 μl, before being quantified by
Micro BCA™ Protein Assay Kit (ThermoFisher Scientific)
and Flamingo (Bio-Rad, Hercules, CA) fluorescent pro-
tein gel staining.
NL-based enzyme-linked immunosorbent assay (ELISA)
for Ecto-GPR37
CSF ecto-GPR37 was measured with the home-made
competitive ELISA method. In brief, streptavidine-
coated 96-well white plates (ThermoFisher Scientific)
were blocked with serum-free DMEM medium (100 μl/
well) for 1 h at 22 °C. After washing (3 × 1min) with
ELISA buffer (25 mM Tris base, 150 mM NaCl, 0.1%
BSA, 0.05% Tween-20, pH 7.2), the wells were coated
with 100 μl of anti-rabbit IgG-biotin antibody (10 μg/ml,
Sigma Aldrich) in the ELISA buffer for 2 h at 22 °C. Sub-
sequently, the plates were washed with the ELISA buffer
(3 × 1min) and incubated with rabbit anti-GPR37
(mouse) or rabbit anti-GPR37 (human) antibody (1 μg/
ml in ELISA buffer) for 2 h at 22 °C. Then, 3 μl of either
mouse or human CSF was added to each well containing
47 μl of ELISA buffer and incubated overnight at 4 °C in
a humid chamber. Next day, the plates were washed (3
times, 1 min each) with ELISA buffer and incubated with
50 μl of purified ecto-GPR37NL (mouse) or ecto-
GPR37NL (human) (50.000 relative light units [RLU]/μl
in ELISA buffer) for 1 h at 22 °C in the dark. Finally, the
plates were washed (3 × 1min) with ELISA buffer and
90 μl of ELISA buffer was added to each well before in-
corporating 10 μl of ELISA buffer solution containing
10 μM coelenterazine 400a (NanoLight Technologies,
Pinetop, AZ). After 1-min incubation, the end-point lu-
minescence was determined using a CLARIOstar
Optima plate-reader (BMG Labtech GmbH, Ortenberg,
Germany) and the output luminescence was reported as
the integral RLU. In addition, a standard curve was gen-
erated using known concentrations of either mouse or
human ecto-GPR37SNAP in each experiment.
α-Synuclein ELISA
The α-synuclein concentration was measured using the
LEGEND MAX™ Human α-Synuclein ELISA Kit
(844101, BioLegend, San Diego, CA) according to the
manufacturer’s instructions. Briefly, a microtiter plate
pre-coated with the capture antibody was washed 4
times, added with 20 μl of CSF at 1:10 dilution in re-
agent buffer, and incubated overnight at 4 °C with shak-
ing. Next day, the plate was washed 4 times, followed by
addition of the biotinylated detection antibody to each
well and incubation for 2 h at room temperature (RT).
The unbound detection antibody was removed by 4
washes. The streptavidin-HRP conjugate was added to
each well, incubated for 1 h at RT and then the plate
was washed 4 times to remove the remaining conjugate.
Finally, chemiluminescent substrate was added to each
well and signals were read using a Tecan Spark 10M
plate reader (Tecan Nordic AB, Stockholm, Sweeden).
Statistical analysis
Data are presented as mean ± standard error of mean
(SEM) and were analysed by Student’s t test or one-way
analysis of variance (ANOVA) with Dunnett’s post-hoc
test using GraphPad Prism 6.01 (San Diego, CA). P <
0.05 was considered as statistically significant. The distri-
bution of CSF ecto-GPR37 did not follow Gaussian dis-
tribution (Shapiro-Wilk normality test, P < 0.05), so the
data were analysed with non-parametric Mann-Whitney
U-tests. The diagnostic accuracy by CSF ecto-GPR37
levels was assessed using the receiver operating charac-
teristic (ROC) curve analysis. The correlation coefficients
(rho) were calculated using the Spearman two-tailed cor-
relation test.
Results
GPR37 density in post-mortem SN from NC and PD
subjects
Metalloprotease-mediated GPR37 N-terminus cleavage
leads to ectodomain shedding in a heterologous expres-
sion system [13]. This posttranslational modification, to-
gether with N-glycosylation, generates a heterogenous
pattern of GPR37 species that can be detected by im-
munoblotting, namely the precursor, the full-length ma-
ture and some N-terminus-cleaved receptor forms [13].
Here, we first assessed GPR37 density in human SN by
immunoblotting using a specific antibody against human
GPR37 C-terminal domain (anti-GPR37-C) [18]. The
immunoblotting results revealed a wide-range of GPR37
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protein bands (Fig. 1a) compatible with the putative pre-
cursor (67 kDa), the full-length mature (93 kDa) and sev-
eral GPR37 N-terminus-cleaved forms (76 kDa, 52 kDa,
47 kDa, 43 kDa and 39–40 kDa) already described [13].
This is consistent with a recent report of band pattern
using a commercial anti-GPR37 C-terminal-domain
antibody (RRID: AB_2799658) (https://www.cellsignal.
com/products/primary-antibodies/gpr37-d4c8h-rabbit-
mab/64407). These results indicate that in human native
tissues (e.g. SN), GPR37 may be N-terminally processed,
thus suggesting the existence of a heterogenous pattern
of GPR37 species.
GPR37 accumulates in SN LBs of PD patients [35],
thus we next assessed the density of the different N-
terminally processed forms of GPR37 in SN of PD sub-
jects. The GPR37 precursor density did not increase
throughout the different Braak PD stages assayed, but
the N-terminal-cleaved forms were significantly (P =
0.0057) increased at Braak PD stage 6 (Fig. 1b), render-
ing an average of 214% ± 42% increase of density (P =
0.0462) when all the GPR37 forms (i.e. precursor plus
N-terminus cleaved forms) were considered (Fig. 1b).
These results indicated an overall increased density of
GPR37 in SN of PD subjects, particular the N-terminal-
cleaved forms of the receptor. Moreover, RT-qPCR ana-
lysis showed a significant (P = 0.0011) 3.1-fold increase
in GPR37 mRNA expression in SN of Braak PD stage 5/
6 subjects as compared to the NC subjects (Fig. 1c). Col-
lectively, these results confirmed an upregulation of
GPR37 expression in sporadic PD and a concomitant in-
crease in N-terminally cleaved forms of GPR37.
Ecto-GPR37 in CSF
To test if GPR37 shedding also occurs in native tissue,
we monitored GPR37 in vivo shedding by detecting the
excised N-terminus of GPR37 (i.e. ecto-GPR37) in the
CSF. To confirm the identity of ecto-GPR37 in CSF, we
immunoprecipitated ecto-GPR37 using the anti-GPR37-
N antibody and the isolated peptides were analysed by li-
quid chromatography coupled to mass spectrometry (see
Supplementary Methods). Six unique peptides corre-
sponding to the N-terminal domain of the human
GPR37 in pooled CSF samples from NC and PD patients
were detected (Fig. 2). Ecto-GPR37 peptides, especially
the EEQGAAFLAGPSWDLPAAPGRDPAAGR peptide,
showed an overall increased abundance in CSF from PD
patients when compared to that from NC subjects (Fig.
2a). Indeed, these results were consistent with the in-
creased density of N-terminally cleaved forms of the re-
ceptor shown in the immunoblot analysis of post-
mortem SN from PD subjects (Fig. 1a and b).
Subsequently, we developed an in-house species-
specific NL-based ELISA assay to detect either mouse or
human ecto-GPR37 at the extracellular milieu (i.e. CSF).
First, we engineered specific mouse or human GPR37
constructs containing HA and NL tags at the N-
terminus (Fig. 3a) to allow their purification and further
luminescence detection (Fig. 3b and c). The recombinant
Fig. 1 GPR37 protein density and mRNA levels in post-mortem brain tissues from neurological controls (NCs) and Parkinson’s disease (PD)
subjects. a Immunoblots showing the expression of GPR37 in the SN of NC and PD subjects (Braak PD stage 4, Braak PD 5 and Braak PD 6).
Extracts from the human post-mortem SN were analysed by SDS-PAGE and immunoblotted using rabbit anti-GPR37-C and rabbit anti-α-actinin
antibodies. The right dashed outlined area (*) is shown with enhanced contrast and corresponds to lane 1 (NC). The different GPR37 forms
included precursor (70 kDa), full-length mature (93 kDa) and GPR37 N-terminus-cleaved forms (76 kDa, 52 kDa, 47 kDa, 43 kDa and 39–40 kDa). b
Relative quantification of GPR37 protein density in the SN. The immunoblots corresponding to the precursor (Pre) and cleaved GPR37 forms from
the NC (n = 5), Braak PD stage 4 (n = 5), Braak PD stage 5 (n = 5) and Braak PD stage 6 (n = 5) subjects were quantified by densitometric scanning.
Values were normalized to α-actinin in each lane to correct for protein loading. Results are expressed as the percentage (mean ± SEM) of the NC.
*P < 0.05, **P < 0.01 vs NC, one-way ANOVA followed by Dunnett’s post-hoc test. c RT-qPCR assessment of GPR37 mRNA expression in post-
mortem SN from NCs (n = 10), Braak PD stage 3/4 (n = 7) and Braak PD stage 5/6 (n = 17) subjects. Mean values of the housekeeping genes (GUS-
B, XPNPEP1, AARS and HPRT) were used to normalize samples. Results are expressed as fold-change (mean ± SEM) of the NCs. **P < 0.01 vs NC,
one-way ANOVA followed by Dunnett’s post-hoc test
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mouse or human ecto-GPR37NL protein was used as a
tracer in an ELISA assay operated with a rabbit anti-
mouse/human GPR37-N polyclonal antibody captured
to microplates coated with an anti-rabbit antibody. In-
deed, the sensitivity of the ELISA assay was previously
assessed by performing competition assays with recom-
binant mouse or human ecto-GPR37SNAP protein (data
not shown). Subsequently, we determined the ecto-
GPR37 density in mouse and human CSF. First, CSF
from wild-type and GPR37−/− mice was assayed with the
specific mouse GPR37-NL-based ELISA assay. While
significant amount of ecto-GPR37 was detected in the
CSF from GPR37+/+ mice, which was determined to be
286.8 ± 77.3 pg/ml, ecto-GPR37 was undetectable in all
CSF volumes from the GPR37−/− mice assayed (Fig. 3d).
These results indicate that the specific mouse ecto-
GPR37 ELISA assay unequivocally detected ecto-GPR37
in the mouse CSF.
Next, we analysed post-mortem human CSF from a
small cohort (n = 8) of NC and PD subjects using the
specific human GPR37 NL-based ELISA assay. While
the NCs had an average ecto-GPR37 content of 185 ±
17 pg/ml in the CSF, the PD patients had 282 ± 18 pg/ml
ecto-GPR37 in the CSF. Thus, ecto-GPR37 was signifi-
cantly (P = 0.019) increased in the CSF of PD patients
(Fig. 3e). Subsequently, a larger and different cohort of
Fig. 2 Ecto-GPR37 peptides detected in human CSF. a Mass spectrometric results (see Supplementary Methods) of human ecto-GPR37 peptides
immunoprecipitated from the pooled CSF of NC (n = 10) or PD subjects (n = 10). The detected peptide sequences in the CSF of NC and PD are
indicated (M + H+) and their estimated abundance was expressed as the area from the extracted ion chromatograms (XIC) of the peptide
chromatographic peak. NA, not quantified. b Schematic representation showing the precise location of the mass spectrometry-detected ecto-
GPR37 peptides (black circles) within the N-terminal domain (N-term) of the receptor. The theoretical molecular weight (kDa) based on the amino
acid sequence of human GPR37 is indicated (arrows). The seven transmembrane (TM) domains of the receptor embedded within the membrane
are highlighted in grey. The three extracellular loops (ECL) are also indicated. The GPR37 scheme was made using the GPCRdb resource [36]
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NC (n = 45) and PD (n = 41) subjects was assayed. Again,
significantly higher levels of CSF ecto-GPR37 were
found in the PD subjects (334 ± 28 pg/ml) when com-
pared to the NCs (159 ± 21 pg/ml) (P = 0.001) (Fig. 4a).
ROC curve analysis demonstrated that the human
GPR37 NL-based ELISA assay could differentiate PD
subjects (n = 41) from NCs (n = 45), with the area under
the curve (AUC) of 0.808 (0.713–0.900) (P < 0.0001)
(Fig. 4b). The assay, with a cut-off value of 200 pg/ml,
had a sensitivity of 73%, a specificity of 73%, a positive
predictive value of 71%, and a negative predictive value
of 75% for PD diagnosis (Fig. 4b). In addition, no statisti-
cally significant correlations between age/gender and CSF
ecto-GPR37 levels were observed in neither the NC nor the
PD group (Fig. S1). Also, there were no correlations be-
tween the ecto-GPR37 levels in the PD group and the main
clinical features monitored (Table 1, Fig. S2).
Since α-synuclein has attracted considerable attention
as a potential molecular biomarker for PD, we analysed
the α-synuclein content in the CSF of the same PD co-
hort (Table 1). No significant difference in the total α-
synuclein concentration in the CSF was found between
the NC and PD subjects (1049 ± 39 pg/ml vs 1061 ± 37
pg/ml, P = 0.4692) (Fig. 4c). The corresponding ROC
curve analysis showed that the α-synuclein ELISA assay
could not discriminate between the NC and PD subjects
Fig. 3 Detection of ecto-GPR37 by the NanoLuc (NL)-based immunoassay. a Schematic representation showing the putative metalloproteinase
(scissors)-mediated cleavage and shedding of the GPR37 N-terminal domain (i.e. ecto-GPR37) in a GPR37 construct containing the HA (filled red
circle) and NL tags at its N-terminus (i.e. ecto-GPR37NL). Upon expression in HEK-293 cells, the GPR37NL ectodomain was released by shedding
and detected in the culture medium by monitoring its NL enzymatic activity after incubation of the growth medium of cells transfected with
mock (Veh) or mouse (b)/human (c) GPR37NL with coelenterazine 400a and determination of the luminescence (RLU, relative light units). d
Assessment of ecto-GPR37 in 1 μl, 3 μl and 5 μl of cerebrospinal fluid of GPR37+/+ and GPR37−/− mice. The purified mouse ecto-GPR37NL was used
as a tracer in the competitive ELISA. Results are expressed as RLU (mean ± SD, n = 3). Dashed line represents the RLUmax (i.e. RLU in the absence
of CSF). *P < 0.05 and **P < 0.01 vs RLUmax, one-way ANOVA followed by Dunnett’s post-hoc test. e Assessment of ecto-GPR37 in post-mortem
CSF from NC (n = 8) and PD (n = 8) subjects from Bellvitge Hospital using the GPR37-NL-based ELISA assay. **P < 0.01, Student’s t-test
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(AUC = 0.5407, P = 0.5402) (Fig. 4d). Overall, the results
suggested that the CSF total α-synuclein could not dis-
tinguish PD patients from control subjects.
Last, we assessed whether the CSF ecto-GPR37 had a
specific role in the diagnosis of AD, the most common
neurodegenerative disorder. To this end, we first evalu-
ated GPR37 mRNA expression levels in the FC and EC
from NC and Braak AD stage 3/4 and 5/6 subjects
(AD3/4 and AD5/6, respectively) by RT-qPCR. There
were no significant changes in GPR37 mRNA expression
in either FC or EC among NC, AD3/4 and AD5/6 sub-
jects (Fig. 5a and b). Subsequently, we evaluated the
ecto-GPR37 content in the CSF from NC and AD pa-
tients using the GPR37 NL-based ELISA assay, and
found no significant difference between the NC (203 ±
42 pg/ml) and AD (304 ± 61 pg/ml) subjects (P = 0.1266;
Fig. 5c). The corresponding ROC curve analysis showed
that the human GPR37 NL-based ELISA assay could not
discriminate between the NC and AD subjects (AUC =
0.6107, P = 0.2036) (Fig. 5d). Although PD and AD path-
ologies share impaired biological processes, our results
suggest a differential molecular mechanism of GPR37
expression and CSF ecto-GPR37 levels between AD and
PD. Thus, further studies are required to characterize
GPR37 biology in AD.
Discussion
Although GPR37 has been postulated to be the receptor
for the neuroprotective and glioprotective factors pro-
saptide and prosaposin [37, 38], the precise physiological
function of the receptor remains elusive. Recent studies
have reported some alternative functions of GPR37, such
as the chaperone-like activity that controls the cell sur-
face targeting and function of adenosine and dopamine
receptors [18, 39], and participation in the Wnt co-
receptor LRP6 maturation [40]. Remarkably, it has been
demonstrated that the GPR37 N-terminus is processed
by MPs, leading to the generation of different GPR37 N-
Fig. 4 Detection of ecto-GPR37 and α-synuclein in CSF of NC and PD participants from Karolinska Hospital. a The CSF ecto-GPR37 level was
significantly higher in PD patients than in NCs, irrespective of sex. b ROC curve analysis of CSF ecto-GPR37. c CSF α-synuclein did not differ
between the NC and PD participants. d ROC curve analysis of CSF α-synuclein. *P < 0.05, ****P < 0.0001 (Mann-Whitney U-tests)
Morató et al. Translational Neurodegeneration            (2021) 10:8 Page 10 of 14
terminally cleaved forms [13]. While frequently de-
scribed in the processing of single-pass membrane-
anchored proteins, the MP-mediated shedding is less
common in post-translational modification of GPCRs
[41]. The N-terminal ectodomain of GPR37 has been
found to be susceptible to the MP-mediated cleavage,
which occurs constitutively in the absence of any exter-
nal stimulation and leads to the shedding of the receptor
N-terminus (i.e. ecto-GPR37). Interestingly, although the
GPR37 precursors are efficiently converted into the ma-
ture receptor forms (i.e. fully glycosylated forms) and
targeted to the plasma membrane, by far most cell sur-
face receptors exist in a cleaved form under steady-state
homeostatic conditions. Therefore, it can be speculated
that in neurodegenerative conditions which develop with
GPR37 overexpression and/or MP alterations, as in PD
[14], the ecto-GPR37 levels may mirror the neural dam-
age during disease progression.
In the present study, the presence of ecto-GPR37 pep-
tides in human CSF was first revealed by mass spec-
trometry. Interestingly, all the ecto-GPR37 peptides
found in the CSF of NC subjects (Fig. 2b) corresponded
to the N-terminal amino acid sequences upstream the
most abundant cleaved form of the receptor (i.e. 43 kDa)
detected in our immunoblot experiments. This observa-
tion was compatible with the occurrence of constitutive
shedding of the receptor in vivo, thus reinforcing the
biological relevance of this process for GPR37. In
addition, the immunoblotting detection of GPR37 in PD
SN revealed upregulation of a prominent 52-kDa recep-
tor form, which correlated with the increased CSF dens-
ity of upstream N-terminal peptides, especially the
EEQGAAFLAGPSWDLPAAPGRDPAAGR and GRDA
WGPGNSAR peptides. The precise molecular mecha-
nisms underlying the differential GPR37 shedding in PD
require further investigation.
The human GPR37 NL-based ELISA assay allowed re-
producible measurement of ecto-GPR37 levels in CSF
samples. Here, we found significantly higher levels of
ecto-GPR37 in the CSF of PD patients compared to that
in the NCs in two independent clinical cohorts, consist-
ent with the higher density of CSF ecto-GPR37 peptides
revealed by the proteomic analysis. Interestingly, our
findings showed that the CSF ecto-GPR37 achieved
Fig. 5 GPR37 mRNA expression and ecto-GPR37 levels in AD. GPR37 mRNA expression in post-mortem frontal cortex (a) and entorhinal cortex (b)
from NCs (panel a: n = 17; b: n = 5), Braak AD stage 3/4 (a: n = 9; b: n = 4) and Braak AD stage 5/6 (a: n = 20; b: n = 5) subjects was assessed by RT-
qPCR. Mean values of the housekeeping genes (GUS-B, XPNPEP1, AARS and HPRT) were used to normalize samples. Results are expressed as fold-
change (mean ± SEM) of the NCs. c Detection of ecto-GPR37 in the CSF from NC (n = 22) and AD (n = 23) participants recruited at the University
Medical School of Göttingen. d ROC curve analysis of CSF ecto-GPR37
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diagnostic performance when the CSF samples from the
PD patients were analyzed and compared to the NC sub-
jects. The finding of no correlations between clinical rat-
ings and the CSF content of ecto-GPR37 in the PD
patients may be related to the fact that this part of the
study was underpowered. The lack of correlation with
the UPDRS motor scores may be because that the clin-
ical ratings were performed when the patients were ON,
i.e. they took their daily treatments before the visit to
the clinics. In addition, here we found no alterations of
the CSF total α-synuclein in the same PD cohort, which
was consistent with previous reports [42–47]. However,
there were also studies reporting lower levels of total α-
synuclein in the CSF of PD subjects [48]. Other studies
have found that the total CSF α-synuclein in PD overlaps
with that found in different diseases, thus being not pos-
sible to discriminate between patients with synucleino-
pathies and cognitively normal subjects suffering from
other non-neurodegenerative diseases [43]. Finally, two
meta-analytic reviews of the existing data revealed that
the CSF total α-synuclein is lower in PD patients com-
pared to controls [44, 45]. The sensitivity and specificity
for distinguishing PD from controls were 0.72 and 0.65
[44] or 0.88 and 0.4 [45], respectively, and the ROC
curve showed an AUC of 0.73 [45]. Thus, while the total
CSF α-synuclein by itself shows a low diagnostic accur-
acy and does not seem to be a reliable PD diagnostic
marker, it may provide a higher accuracy in PD diagno-
sis when combined with other biomarkers [4, 5]. Instead,
the real-time quaking-induced conversion (RT-QuIC)
assay detected α-synuclein aggregation in PD CSF with a
sensitivity of 95% and a specificity of 100% when com-
pared to control CSF [46]. However, RT-QuIC is time-
consuming (several days) and cumbersome to perform.
In addition to the CSF biomarkers, DatScan SPECT im-
aging is clinically used to aid PD diagnosis, and has an
AUC value of 0.92–0.96 in distinguishing PD from con-
trols [47]. However, the DatScan SPECT is expensive
and, from the pathological perspective, it does not per-
form well to predict the number of nigral neurons in PD
[48]. Therefore, there is still a need for novel fluid bio-
markers of PD that are inexpensive and easy to perform.
Interestingly, here we found no significant increase of
CSF ecto-GPR37 in AD patients compared to the NCs.
AD is pathologically characterized by the accumulation
of Aβ and pathologically modified tau proteins to form
senile plaques and NFTs, respectively [49]. In addition,
AD patients often present with accumulation of other
proteins including α-synuclein and TDP-43, which may
play a pathogenic role in AD and/or reflect the diversity
of AD pathophysiology. Thus, biomarkers based on
these proteins are widely considered as useful diagnostic
markers of AD. The results of CSF ecto-GPR37 in AD
suggest different pathological participation of GPR37 in
PD versus AD. The differential diagnostic value of
GPR37 in PD and AD may be useful for discriminating
combined neurodegenerative pathologies, thus allowing
correct stratification of these brain disorders, especially
at early stage. Further longitudinal studies combining
CSF ecto-GPR37 with reliable biomarkers for neurode-
generative diseases are needed. In addition, it would be
necessary to explore whether the CSF ecto-GPR37 can
be used for the differential diagnosis between PD and
atypical parkinsonism, including LB dementia, multiple
system atrophy, progressive supranuclear palsy and cor-
ticobasal syndrome. Moreover, future studies are needed
to elucidate whether the CSF ecto-GPR37 can assist in
discriminating the PD patients who will develop a cer-
tain phenotype, e.g. PD dementia, and/or those who will
have a rapid disease progression.
Conclusion
In this study, we reported, for the first time, that signifi-
cantly higher levels of ecto-GPR37 were detectable in
the CSF of PD patients. In addition, the CSF ecto-
GPR37 achieved good diagnostic performance for PD, in
contrast to the total α-synuclein performance. Interest-
ingly, the ecto-GPR37 levels were not increased in the
CSF of AD subjects. Thus, our study provides strong evi-
dence supporting CSF ecto-GPR37 as a promising bio-
marker of PD. Hence, the CSF ecto-GPR37 levels may
evolve into a measurement of PD neuropathology, com-
plementing the existing biomarkers. Future studies
should be performed to explore the potential use of
ecto-GPR37 in combination with other
neurodegeneration-related biomarkers in clinical re-
search, trials and practice.
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